Rongheng

Suzhou Rongheng Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's research efforts are primarily focused on high-impact therapeutic areas, including oncology, metabolic disorders, and autoimmune diseases. Its lead candidate, RH001, is a small molecule inhibitor currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors. Supported by prominent venture capital firms such as Oriza Holdings and SBCVC, Rongheng leverages its internal R&D capabilities to advance a pipeline of novel drug candidates. The company aims to address significant unmet medical needs by delivering high-quality, affordable innovative medicines to the global market.